We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
20 Oct 2021 - 22 Oct 2021
21 Oct 2021 - 24 Oct 2021
Virtual Venue

Liquid Bioassay for Ultrasensitive Detection of Circulating HPV DNA

By LabMedica International staff writers
Posted on 04 Oct 2021
Print article
Image: The HPV-Seq test is an ultra-sensitive liquid biopsy solution for the identification and quantification of circulating HPV 16 and HPV 18 DNA in patients with cancers caused by HPV infection (Photo courtesy of Sysmex Inostics)
Image: The HPV-Seq test is an ultra-sensitive liquid biopsy solution for the identification and quantification of circulating HPV 16 and HPV 18 DNA in patients with cancers caused by HPV infection (Photo courtesy of Sysmex Inostics)
A recent paper concluded that for cancers caused by the human papillomavirus (HPV), the HPV-seq technique was a promising ultrasensitive approach for detection and analysis of circulating tumor DNA (ctDNA).

HPV DNA offers a convenient ctDNA marker for HPV-associated cancers, but current methods such as digital PCR (dPCR) provide insufficient accuracy for clinical applications in patients with low-disease burden. In this light, investigators at Princess Margaret Cancer Centre (Toronto, Canada) asked whether a next-generation sequencing approach (HPV-seq) could provide quantitative and qualitative assessment of HPV ctDNA in low-disease-burden settings.

The classical PCR test carries out one reaction per single sample. The digital PCR (dPCR) method also carries out a single reaction within a sample, however the sample is separated into a large number of partitions and the reaction is carried out in each partition individually. This separation allows a more reliable collection and sensitive measurement of nucleic acid amounts. The dPCR method has been demonstrated as useful for studying variations in gene sequences - such as copy number variants and point mutations - and it is routinely used for clonal amplification of samples for next-generation sequencing.

The HPV-seq test is an ultra-sensitive liquid biopsy approach for the identification and quantification of circulating HPV 16 and HPV 18 DNA in patients with cancers caused by HPV infection, including cervical cancer, anal squamous cell carcinoma, and head and neck squamous cell cancer. HPV-seq detects cell-free HPV DNA across a large dynamic range and demonstrates accurate quantification even when few copies are present, enabling high-resolution molecular monitoring.

For the current study, the investigators conducted pre-clinical technical validation studies on HPV-seq and applied it retrospectively to a prospective multicenter cohort of locally-advanced cervix cancer patients and a cohort of oropharynx cancer patients. HPV-seq results were compared with those obtained by dPCR.

Results revealed that HPV-seq achieved reproducible detection of circulating HPV DNA at levels that were up to 20-fold lower than those detectable by dPCR. Detectable HPV ctDNA at end-of-treatment was associated with inferior progression free survival with 100% sensitivity and 67% specificity for recurrence. Accurate HPV genotyping was successful from 100% of the pre-treatment samples.

"Increasingly, as clinicians we are focused on precision medicine and making sure we are not over-treating people while still curing them. That is a very difficult balance to strike," said senior author Dr. Scott Bratman, assistant professor of radiation oncology and medical biophysics at Princess Margaret Cancer Centre. "We are really at the cusp of a revolution from a technology, clinical implementation, and standard of care standpoint, where five to 10 years from now we will not be treating everybody with the same dose of radiation and chemotherapy, and then waiting months to see if the treatment was effective. I am confident we will be giving much more tailored doses. Patients who need more treatment will then be able to continue on, or different treatments can be added. We can spare the vast majority of patients who will not need those interventions and provide them with a greater quality of life once they are cured of the cancer."

The HVP DNA bioassay paper was published in the September 27, 2021, online edition of the journal Clinical Cancer Research.

Related Links:
Princess Margaret Cancer Centre

Gold Supplier
Fully Automated Batch Immunoanalyzer
Laboratory Water System
Cardiovascular Disease POC Analyzer
cobas h 232 POC System
Laboratory Automation System

Print article


Clinical Chem.

view channel
Image: Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels (Photo courtesy of Quanterix)

Plasma Amyloid-β 42/40 Assays Compared in Alzheimer Disease

Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of... Read more


view channel
Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)

Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and... Read more


view channel
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Biosciences)

Highly Multiplexed Cell Surface Protein Analyzed Via Flow Cytometry

Modern immunologic studies increasingly requires high-dimensional analyses to understand the complex milieu of cell types that comprise the tissue microenvironments of disease. One of the cornerstones... Read more


view channel
Image: Characteristic bronchoalveolar lavage findings of diffuse alveolar hemorrhage (Photo courtesy of Peter C. Bauer, MD)

Bronchoalveolar Lavage Cell Pattern Determined for Diffuse Alveolar Hemorrhage

Diffuse alveolar hemorrhage (DAH) is a clinicopathological syndrome that describes the accumulation of intra-alveolar red blood cells originating from the alveolar capillaries. DAH can induce severe respiratory... Read more


view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.